Evaluating blood tests for advanced cancer patients
Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy
This study is testing if a new blood test that looks for cancer DNA can help doctors make better treatment decisions for patients with advanced gastrointestinal cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Trial ID | NCT06290856 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the clinical utility of circulating tumor DNA (ctDNA) assays in patients with advanced gastrointestinal malignancies, including metastatic colorectal cancer, pancreatic adenocarcinoma, and cholangiocarcinoma. The researchers will evaluate the effectiveness of a low-cost multiplex PCR platform for detecting specific mutations and monitoring treatment resistance. The study will focus on how these ctDNA assays can inform clinical decision-making and improve diagnostic pathways in routine practice.
Who should consider this trial
Good fit: Ideal candidates include newly referred patients with advanced pancreatic cancer, cholangiocarcinoma, or metastatic colorectal cancer.
Not a fit: Patients with early-stage cancers or those not diagnosed with the specified advanced malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the precision of cancer diagnostics and treatment monitoring for patients with advanced malignancies.
How similar studies have performed: Other studies have shown promise in using ctDNA assays for cancer diagnostics, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Newly referred patients with advanced pancreatic cancer (\~20/year), Cholangiocarcinoma (\~20/year), metastatic colorectal cancer (mCRC) (\~50/year) and anti-EGFR-treated mCRC patients (\~10/year) to Oslo University Hospital are eligible for inclusion.
Where this trial is running
Oslo
- Oslo university Hospital — Oslo, Norway (Recruiting)
Study contacts
- Principal investigator: Ragnhild Nome, MD,PhD — Oslo University Hospital
- Study coordinator: Ragnhild Nome, MD, PhD
- Email: ragnom@ous-hf.no
- Phone: 98602658
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.